Radiation Recall

 

Radiation recall is a severe skin reaction that occurs when certain chemotherapy drugs are administered during or soon after radiation treatment. The rash appears like a severe sunburn. Treatment generally consists of corticosteroids to reduce inflammation, and rarely, chemotherapy is delayed until the skin heals.

What is radiation recall?

Radiation recall is a severe skin reaction that develops when chemotherapy is administered during or soon after radiation treatment. It usually appears on the area of skin where the radiation was administered several weeks to months after the radiation was administered.

What causes radiation recall?

The chemotherapy drugs that have been reported to cause radiation recall in more than 10 percent of patients include:

  • Cosmegen® (actinomycin)
  • Adriamycin® (doxorubicin)
  • Rheumatrex® (methotrexate)
  • 5-FU (fluorouracil)
  • Hydrea® (hydroxyurea)
  • Taxol® (paclitaxel)
  • Doxil® (liposomal doxorubicin)

What are the symptoms of radiation recall?

Radiation recall is a rash that appears like a severe sunburn. It is characterized by one or more of the following:

  • Redness
  • Tenderness
  • Swelling
  • Wet sores
  • Peeling skin
  • Discoloration after the skin has healed

What is the treatment for radiation recall?

In some cases, symptoms may be severe enough that chemotherapy may have to be delayed until your skin heals. Usually, your doctor will try to give you medication to reduce the inflammation so that you can continue receiving the chemotherapy. Corticosteroids, in the form of a pill or a cream, may be prescribed for this purpose.

What else can I do?

It is very important to protect the skin that is irritated:

  • Stay out of the sun
  • Use sunscreens when you must be exposed
  • Avoid tanning beds
  • Wear loose, nonrestrictive clothing

This content was last modified on August 24, 2007 .
Latest Cancer News
Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Cystoscopy Remains Best Method for Surveillance of Patients with Bladder Cancer

March 10, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that cystoscopy alone remains the most cost-effective method of detecting recurrent superficial bladder cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Select news items provided by Reuters Health